Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

  title={Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.},
  author={Robert J. Kreitman and Ira Pastan},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={17 20},
Recombinant immunotoxins are fusion proteins that contain the cytotoxic portion of a protein toxin fused to the Fv portion of an antibody. The Fv binds to an antigen on a target cell and brings the toxin into the cell interior, where it arrests protein synthesis and initiates the apoptotic cascade. Moxetumomab pasudotox, previously called HA22 or CAT-8015, is a recombinant immunotoxin composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38-kDa fragment of Pseudomonas… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 66 extracted citations


Publications referenced by this paper.
Showing 1-10 of 63 references

Complete remissions in 3 of 12 patients with pediatric acute lymphoblastic leukemia (ALL) during phase I testing of the anti-CD22 immunotoxin moxetumomab pasudotox

  • A Wayne, D Bhojwani, K Richards, M Stetler-Stevenson, LB Silverman, S Jeha
  • Proceedings of the 52nd ASH Annual Meeting;
  • 2010
Highly Influential
15 Excerpts

Stabilization of the Fv fragments in recombinant immunotoxins by CCRFOCUS Clin Cancer Res

  • Y Reiter, U Brinkmann, RJ Kreitman, S-H Jung, B Lee, I. Pastan
  • Clinical Cancer Research 6404 on October
  • 2011

Similar Papers

Loading similar papers…